161 related articles for article (PubMed ID: 26913587)
1. What do women with breast cancer expect from their treatment? Correlates of negative treatment expectations about endocrine therapy.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Rief W; Witzel I; Albert US; Nestoriuc Y
Psychooncology; 2016 Dec; 25(12):1485-1492. PubMed ID: 26913587
[TBL] [Abstract][Full Text] [Related]
2. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study.
Nestoriuc Y; von Blanckenburg P; Schuricht F; Barsky AJ; Hadji P; Albert US; Rief W
Ann Oncol; 2016 Oct; 27(10):1909-15. PubMed ID: 27551051
[TBL] [Abstract][Full Text] [Related]
3. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
4. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
[TBL] [Abstract][Full Text] [Related]
5. The importance of nonpharmacogenetic factors in endocrine therapy.
McCowan C; Thompson AM
Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
[TBL] [Abstract][Full Text] [Related]
6. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
7. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
8. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
[TBL] [Abstract][Full Text] [Related]
9. Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study.
Thorneloe RJ; Horne R; Side L; Wolf MS; Smith SG;
Clin Breast Cancer; 2019 Feb; 19(1):e116-e126. PubMed ID: 30518498
[TBL] [Abstract][Full Text] [Related]
10. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
11. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
12. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
13. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
14. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
15. Quality of life issues during adjuvant endocrine therapy.
Fallowfield L; Jenkins V
Cancer Treat Res; 2009; 151():353-65. PubMed ID: 19593523
[No Abstract] [Full Text] [Related]
16. Framing and personalizing informed consent to prevent negative expectations: An experimental pilot study.
Heisig SR; Shedden-Mora MC; Hidalgo P; Nestoriuc Y
Health Psychol; 2015 Oct; 34(10):1033-1037. PubMed ID: 25689300
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant endocrine therapy in breast cancer].
Huober J; Thürlimann B
Ther Umsch; 2008 Apr; 65(4):193-200. PubMed ID: 18622910
[TBL] [Abstract][Full Text] [Related]
18. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
19. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
20. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
